Calithera Biosciences Inc (NASDAQ:CALA) shares were up 7.6% on Thursday . The stock traded as high as $6.40 and last traded at $6.24. Approximately 1,034,546 shares were traded during mid-day trading, an increase of 135% from the average daily volume of 440,800 shares. The stock had previously closed at $5.80.
Several research analysts have weighed in on CALA shares. ValuEngine raised shares of Calithera Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, September 11th. Zacks Investment Research cut shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $16.50.
The firm has a market cap of $188.93 million, a price-to-earnings ratio of -7.20 and a beta of 2.48.
Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.09) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.23. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 22.09%. The company had revenue of $17.07 million for the quarter, compared to analysts’ expectations of $5.17 million. On average, research analysts expect that Calithera Biosciences Inc will post -1.27 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in CALA. Schwab Charles Investment Management Inc. increased its holdings in shares of Calithera Biosciences by 12.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 125,935 shares of the biotechnology company’s stock worth $794,000 after purchasing an additional 13,700 shares during the period. BlackRock Inc. increased its holdings in shares of Calithera Biosciences by 11.9% during the first quarter. BlackRock Inc. now owns 3,229,031 shares of the biotechnology company’s stock worth $20,344,000 after purchasing an additional 342,756 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Calithera Biosciences by 159.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 472,394 shares of the biotechnology company’s stock worth $2,976,000 after acquiring an additional 290,037 shares in the last quarter. Citigroup Inc. boosted its position in shares of Calithera Biosciences by 78.4% during the 1st quarter. Citigroup Inc. now owns 23,746 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 10,433 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Calithera Biosciences during the 1st quarter worth approximately $512,000. 54.84% of the stock is currently owned by institutional investors.
Calithera Biosciences Company Profile (NASDAQ:CALA)
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Further Reading: NASDAQ
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.